☰

Deniz A. Ucar, Ph.D. - Publications

Affiliations: 
2010 University of Florida, Gainesville, Gainesville, FL, United States 
Area:
Genetics, Molecular Biology, Pharmacology
Tree Info Grants Similar researchers PubMed Report error

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Hossain F, Ucar DA, Monticone G, Ran Y, Majumder S, Larter K, Luu H, Wyczechowska D, Heidari S, Xu K, Shanthalingam S, Matossian M, Xi Y, Burow M, Collins-Burow B, et al. Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer. Frontiers in Immunology. 14: 1244159. PMID 37901240 DOI: 10.3389/fimmu.2023.1244159  0.368
2021 Hoang VT, Matossian MD, La J, Hoang K, Ucar DA, Elliott S, Burks HE, Wright TD, Patel S, Bhatt A, Phamduy T, Chrisey D, Buechlein A, Rusch DB, Nephew KP, et al. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation. Journal of Cellular Biochemistry. PMID 33876843 DOI: 10.1002/jcb.29916  0.418
2021 Bhatt AB, Wright TD, Barnes V, Chakrabarty S, Matossian MD, Lexner E, Ucar DA, Miele L, Flaherty PT, Burow ME, Cavanaugh JE. Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer. Translational Oncology. 14: 101046. PMID 33761370 DOI: 10.1016/j.tranon.2021.101046  0.464
2021 Bhatt AB, Patel S, Matossian MD, Ucar DA, Miele L, Burow ME, Flaherty PT, Cavanaugh JE. Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling. Biomolecules. 11. PMID 33572742 DOI: 10.3390/biom11020183  0.419
2020 Chang TC, Matossian MD, Elliott S, Burks HE, Sabol RA, Ucar DA, Wathieu H, Zabaleta J, Valle L, Gill S, Martin E, Riker AI, Miele L, Bunnell BA, Burow ME, et al. Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor. Plos One. 15: e0226464. PMID 33035223 DOI: 10.1371/journal.pone.0226464  0.44
2020 Hoang VT, Matossian MD, Ucar DA, Elliott S, La J, Wright MK, Burks HE, Perles A, Hossain F, King CT, Browning VE, Bursavich J, Fang F, Del Valle L, Bhatt AB, et al. ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer. Frontiers in Oncology. 10: 1164. PMID 32850332 DOI: 10.3389/Fonc.2020.01164  0.452
2020 Matossian MD, Burks HE, Elliott S, Hoang VT, Zuercher WJ, Wells C, Drewry DH, Kapadia N, Chang T, Yan T, Windsor GO, Nguyen K, Fang F, Nephew KP, Buechlein A, ... ... Ucar DA, et al. A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways. Anti-Cancer Drugs. 31: 759-775. PMID 32796402 DOI: 10.1097/Cad.0000000000000962  0.45
2020 Hoang VT, Matossian MD, Ucar DA, Elliott S, La J, Wright MK, Burks HE, Perles A, Hossain F, King CT, Browning VE, Bursavich J, Fang F, Del Valle L, Bhatt AB, et al. ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer Frontiers in Oncology. 10. DOI: 10.3389/fonc.2020.01164  0.37
2020 Matossian MD, Elliott S, Burks HE, Wright M, Sabol RA, Hoang VT, Ucar DA, Alfortish A, Zabaleta J, Hossain F, Chang T, Wathieu H, Pashos N, Bunnell B, Moroz K, et al. Abstract C110: Applications of patient-derived triple-negative breast cancer xenografts that represent understudied patients in Louisiana in targeted therapeutic research Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-C110  0.389
2020 Hossain F, Ucar DA, Majumder S, Matossian M, Monticone G, Xu K, Ran Y, Minter L, Xi Y, Burow M, Golde T, Osborne B, Miele L. Abstract P5-04-19: Sulindac sulfide as a non-immune suppressive gamma secretase modifier to target triple negative breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-04-19  0.387
2020 Ucar DA, Monticone G, Hossain F, Majumder S, Wyczechowska D, Dean MJ, Valle LD, Zabaleta J, Ran Y, Shanthalingam S, Chabot AB, Collins-Burow BM, Burrow ME, Osborne B, Golde TE, et al. Abstract 6691: Delivering intra-tumoral immune modulators and targeting cancer stem cells using recombinant- AAVs Immunology. 80: 6691-6691. DOI: 10.1158/1538-7445.Am2020-6691  0.498
2020 Hossain F, Ucar DA, Sanchez-Pino M, Dean M, Majumder S, Wyczechowska D, Monticone G, Sabol R, Xu K, Valle LD, Zabaleta J, Bunnell B, Miele L. Abstract 3866: Investigating tumor infiltrating immune cells signature in obese triple negative breast cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2020-3866  0.395
2019 Hossain F, Ucar DA, Majumder S, Matossian M, Xu K, Ran Y, Minter L, Xi Y, Burow M, Golde T, Osborne B, Miele L. Abstract 3439: Sulindac sulfide as a gamma secretase modifier to target triple negative breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3439  0.392
2018 Hossain F, Sorrentino C, Ucar DA, Peng Y, Matossian M, Wyczechowska D, Crabtree J, Zabaleta J, Morello S, Del Valle L, Burow M, Collins-Burow B, Pannuti A, Minter LM, Golde TE, et al. Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways. Frontiers in Oncology. 8: 575. PMID 30564555 DOI: 10.3389/Fonc.2018.00575  0.369
2018 Hossain F, Majumder S, Ucar DA, Rodriguez PC, Golde TE, Minter LM, Osborne BA, Miele L. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. Frontiers in Immunology. 9: 1288. PMID 29915603 DOI: 10.3389/Fimmu.2018.01288  0.423
2014 Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald SN, Cance WG. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle (Georgetown, Tex.). 13: 2542-53. PMID 25486195 DOI: 10.4161/15384101.2015.941760  0.614
2013 Ucar DA, Magis AT, He DH, Lawrence NJ, Sebti SM, Kurenova E, Zajac-Kaye M, Zhang J, Hochwald SN. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anti-Cancer Agents in Medicinal Chemistry. 13: 595-602. PMID 23272972 DOI: 10.2174/1871520611313040009  0.714
2012 Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, Zajac-Kaye M, Hochwald SN. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle (Georgetown, Tex.). 11: 3250-9. PMID 22894899 DOI: 10.1093/Carcin/Bgr115  0.659
2012 Shaw CM, Grobmyer SR, Ucar DA, Cance WG, Reith JD, Hochwald SN. Elevated expression of IRS2 in the progression from neurofibroma to malignant peripheral nerve sheath tumor. Anticancer Research. 32: 439-43. PMID 22287730  0.515
2012 Moreb JS, Ucar D, Han S, Amory JK, Goldstein AS, Ostmark B, Chang LJ. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chemico-Biological Interactions. 195: 52-60. PMID 22079344 DOI: 10.1016/J.Cbi.2011.10.007  0.377
2012 Gu Y, Lin S, Li JL, Nakagawa H, Chen Z, Jin B, Tian L, Ucar DA, Shen H, Lu J, Hochwald SN, Kaye FJ, Wu L. Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene. 31: 469-79. PMID 21706049 DOI: 10.1038/onc.2011.247  0.629
2011 Ucar DA, Cox A, He DH, Ostrov DA, Kurenova E, Hochwald SN. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma. Anti-Cancer Agents in Medicinal Chemistry. 11: 629-37. PMID 21707510 DOI: 10.2174/187152011796817718  0.667
2011 Ucar DA, Dang LH, Hochwald SN. Focal adhesion kinase signaling and function in pancreatic cancer. Frontiers in Bioscience (Elite Edition). 3: 750-6. PMID 21196348 DOI: 10.2741/E283  0.658
2011 Moreb JS, Ucar D, Han S, Ostmark B, Chang L. Abstract 4361: The enzymatic activity of aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance Cancer Research. 71: 4361-4361. DOI: 10.1158/1538-7445.Am2011-4361  0.413
2011 Ucar DA, Magis A, He D, Ostrov D, Hochwald SN. Abstract 3582: Targeting the FAK amino terminus F2 subdomain to disrupt growth factor receptor protein interactions, signaling and function Cancer Research. 71: 3582-3582. DOI: 10.1158/1538-7445.Am2011-3582  0.714
2011 Gu Y, Lin S, Li J, Nakagawa H, Chen Z, Tian L, Ucar DA, Shen H, Lu J, Hochwald SN, Kaye FJ, Wu L. Abstract 1059: Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion Cancer Research. 71: 1059-1059. DOI: 10.1158/1538-7445.Am2011-1059  0.663
2010 Ucar DA, Hochwald SN. FAK and interacting proteins as therapeutic targets in pancreatic cancer. Anti-Cancer Agents in Medicinal Chemistry. 10: 742-6. PMID 21235432 DOI: 10.2174/187152010794728675  0.662
2009 Zheng D, Kurenova E, Ucar D, Golubovskaya V, Magis A, Ostrov D, Cance WG, Hochwald SN. Targeting of the protein interaction site between FAK and IGF-1R. Biochemical and Biophysical Research Communications. 388: 301-5. PMID 19664602 DOI: 10.1016/J.Bbrc.2009.07.156  0.615
2009 Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chemico-Biological Interactions. 178: 48-55. PMID 18952074 DOI: 10.1016/J.Cbi.2008.09.029  0.461
2009 Kurenova EV, Hunt D, Ucar D, He D, Nyberg C, Hochwald S, Magis A, Ostrov D, Cance WG. Abstract C137: Pinpointing a protein‐protein interaction site of focal adhesion kinase and VEGFR‐3 suppresses cancer growth in vivo Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C137  0.701
2007 Cogle CR, Theise ND, Fu D, Ucar D, Lee S, Guthrie SM, Lonergan J, Rybka W, Krause DS, Scott EW. Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry. Stem Cells (Dayton, Ohio). 25: 1881-7. PMID 17478582 DOI: 10.1634/Stemcells.2007-0163  0.408
Show low-probability matches.